Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pacira BioSciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PCRX
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
ATTENTION Pacira BioSciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats.
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Levi & Korsinsky Announces an Investigation on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira (PCRX) Q3 Earnings Beat Estimates
Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago.
Pacira's Exparel Receives Permanent New Product-Specific J-Code
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
